

Anti-PC4/SUB1 Antibody Picoband™ (monoclonal, 2D13E3)

Catalog # ABO16268

Product Information

Application	WB, FC
Primary Accession	P53999
Host	Mouse
Isotype	Mouse IgG2b
Reactivity	Human
Clonality	Monoclonal
Format	Lyophilized
Description	Anti-PC4/SUB1 Antibody Picoband™ (monoclonal, 2D13E3) . Tested in Flow Cytometry, WB applications. This antibody reacts with Human.
Reconstitution	Adding 0.2 ml of distilled water will yield a concentration of 500 µg/ml.

Additional Information

Gene ID	10923
Other Names	Activated RNA polymerase II transcriptional coactivator p15, Positive cofactor 4, PC4, SUB1 homolog, p14, SUB1, PC4, RPO2TC1
Calculated MW	14395
Application Details	Western blot, 0.25-0.5 µg/ml, Human Flow Cytometry, 1-3 µg/1x10 ⁶ cells, Human
Source	Eukaryota
Contents	Each vial contains 4 mg Trehalose, 0.9 mg NaCl and 0.2 mg Na ₂ HPO ₄ .
Clone Names	Clone: 2D13E3
Immunogen	E.coli-derived human PC4/SUB1 recombinant protein (Position: N62-L127).
Purification	Immunogen affinity purified.
Storage	At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.

Protein Information

Name	SUB1
-------------	------

Synonyms

PC4, RPO2TC1

Function

General coactivator that functions cooperatively with TAFs and mediates functional interactions between upstream activators and the general transcriptional machinery. May be involved in stabilizing the multiprotein transcription complex. Binds single-stranded DNA. Also binds, in vitro, non-specifically to double-stranded DNA (ds DNA).

Cellular Location

Nucleus.

Background

Activated RNA polymerase II transcriptional coactivator p15, also known as positive cofactor 4 (PC4) or SUB1 homolog, is a protein that in humans is encoded by the SUB1 gene. This gene is mapped to 5p13.3. The transcriptional cofactor PC4 is an ancient single-strand DNA (ssDNA)-binding protein that has a homologue in bacteriophage T5 where it is likely the elusive replicative ssDNA-binding protein. The recombinant PC4 is shown to function identically to the native protein through its interaction with TAFs.

Images




Figure 1. Western blot analysis of PC4/SUB1 using anti-PC4/SUB1 antibody (M02698-1).

Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours.

The sample well of each lane was loaded with 30 ug of sample under reducing conditions.

Lane 1: human HeLa whole cell lysates,

Lane 2: human Jurkat whole cell lysates,

Lane 3: human A549 whole cell lysates,

Lane 4: human HepG2 whole cell lysates.

After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with mouse anti-PC4/SUB1 antigen affinity purified monoclonal antibody (Catalog # M02698-1) at 0.5 µg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-mouse IgG-HRP secondary antibody at a dilution of 1:10000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1001) with Tanon 5200 system. A specific band was detected for PC4/SUB1 at approximately 18 kDa. The expected band size for PC4/SUB1 is at 18 kDa.




Figure 2. Flow Cytometry analysis of PC-3 cells using anti-PC4/SUB1 antibody (M02698-1).

Overlay histogram showing PC-3 cells stained with M02698-1 (Blue line). The cells were blocked with 10% normal goat serum. And then incubated with mouse anti-PC4/SUB1 Antibody (M02698-1, 1 µg/1x10⁶ cells) for 30 min at 20°C. DyLight®488 conjugated goat anti-mouse IgG (BA1126, 5-10 µg/1x10⁶ cells) was used as secondary antibody for 30 minutes at 20°C. Isotype control antibody (Green line) was mouse IgG (1 µg/1x10⁶) used under the same conditions. Unlabelled sample (Red line) was also used as a control.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.